About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a leading provider of molecular testing and offers two tests that enable gastroenterologists in determining pancreatic cancer risk.
PancraGEN®, our lead pancreatic cancer test with over 40,000 molecular tests performed, utilizes an “integrated molecular pathology” approach. Utilizing a proprietary combination of tumor suppressor genes, loss of heterozygosity, imaging, chemistries, and other first line testing results, this test classifies patients into one of four distinct risk classifications—from benign to aggressive—that help to inform the best course of action—from surgery to active surveillance.
PancraGEN can be performed on pancreatic cysts, solid tumors, and biliary strictures
PanDNA®, our most recent pancreatic cancer test, provides an alternative molecular testing option to PancraGEN. By identifying cumulative DNA abnormalities in pancreatic cysts and utilizing well-established molecular markers, PanDNA provides insight into cancer risk and helps to inform patient management when used in context with clinical features, imaging, and cytology results.
300 Interpace Parkway
Morris Corporate Center 1, Bldg C
Parsippany, NJ 07054